Scott Smith - Celgene President - Inflammation & Immunology

President

Mr. Scott A. Smith serves as President, Chief Operating Officer of the Company. Prior thereto he was President, Global Inflammation Immunology since August 2014. Previously he was Senior Vice President, Global Head of I I. He joined Celgene in 2008 as Vice President, Global Marketing Inflammation and Immunology. From 2003 to 2008, Mr. Smith was with Biovail, holding positions of General Manager Biovail U.S., General Manager Biovail Canada and Global Commercial Head. As Global Commercial Head for Biovail, he was responsible for global revenue generation, global commercial strategies, business development strategy, and input into global regulatory and clinical development strategies. Prior to Biovail, Mr. Smith was with PharmaciaUpjohn for 16 years where he held various positions including Vice President U.S. Sales, Vice President Marketing Europe based in Paris, Vice President and Commercial Lead for Canada based in Toronto, and Commercial and Regulatory Head for South East Asia based in Hong Kong. Mr. Smith holds a BSc in Chemistry and an HBSc in Pharmacology and Toxicology from the University of Western Ontario and a Masters of International Business Management from the American Graduate School of International Management . Mr. Smith became a member of the Board of Directors of Titan Pharmaceuticals on January 1, 2017. since 2017.
Age 54
Tenure 7 years
Phone908 673-9000
Webwww.celgene.com
Smith holds a BSc in Chemistry and an HBSc in Pharmacology and Toxicology from the University of Western Ontario and a Masters of International Business Management from the American Graduate School of International Management .

Scott Smith Latest Insider Activity

Tracking and analyzing the buying and selling activities of Scott Smith against Celgene stock is an integral part of due diligence when investing in Celgene. Scott Smith insider activity provides valuable insight into whether Celgene is net buyers or sellers over its current business cycle. Note, Celgene insiders must abide by specific rules, including filing SEC forms every time they buy or sell Celgene'sshares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.

Celgene Management Efficiency

The company has return on total asset (ROA) of 0.14 % which means that it generated a profit of $0.14 on every $100 spent on assets. This is way below average. Celgene's management efficiency ratios could be used to measure how well Celgene manages its routine affairs as well as how well it operates its assets and liabilities.
The company currently holds 20.1 B in liabilities with Debt to Equity (D/E) ratio of 199.9, indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Celgene has a current ratio of 3.37, suggesting that it is liquid enough and is able to pay its financial obligations when due. Debt can assist Celgene until it has trouble settling it off, either with new capital or with free cash flow. So, Celgene's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Celgene sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Celgene to invest in growth at high rates of return. When we think about Celgene's use of debt, we should always consider it together with cash and equity.

Similar Executives

Showing other executives

PRESIDENT Age

Steven BradfordHNI Corp
66
Kris YatesHNI Corp
N/A
Mark AndersonAcco Brands
62
Scott BuchholzBlack Hills
58
Lawrence RickettsOne Liberty Properties
47
Israel RosenzweigOne Liberty Properties
77
Donna MeadeHNI Corp
55
Brian IversonBlack Hills
61
Jeffrey GouldOne Liberty Properties
58
Erik KellerBlack Hills
60
Vincent BergerHNI Corp
51
Natalie TeearHudson Pacific Properties
N/A
Jason HagedornHNI Corp
50
Thomas TedfordAcco Brands
53
Patrick BuchenrothAcco Brands
57
David KalishOne Liberty Properties
77
B BullockHNI Corp
43
Marshall BridgesHNI Corp
54
Kimberly NooneyBlack Hills
52
Christopher BartonHudson Pacific Properties
54
Neil McLachlanAcco Brands
57
Celgene Corporation, a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of cancer and inflammatory diseases worldwide. As of November 20, 2019, Celgene Corporation operates as a subsidiary of Bristol-Myers Squibb Company. Celgene operates under Drug ManufacturersGeneral classification in USA and is traded on BATS Exchange. It employs 8852 people. Celgene (CELG) is traded on NASDAQ Exchange in USA and employs 8,852 people.

Management Performance

Celgene Leadership Team

Elected by the shareholders, the Celgene's board of directors comprises two types of representatives: Celgene inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Celgene. The board's role is to monitor Celgene's management team and ensure that shareholders' interests are well served. Celgene's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Celgene's outside directors are responsible for providing unbiased perspectives on the board's policies.
James Loughlin, Independent Director
Michael Friedman, Independent Director
Michael Bonney, Director
Hans Bishop, Director
John Weiland, Director
Gerald Masoudi, Executive Vice President General Counsel and Corporate Secretary
Gilla Kaplan, Independent Director
Patricia Hall, Director
Robert Hugin, Chairman of the Board and Presidentident, CEO
Peter Kellogg, CFO, Executive Vice President
David Elkins, Executive Vice President
Perry Karsen, CEO of Celgene Cellular Therapeutics
Rupert Vessey, President - Research and Early Development
Carrie Cox, Independent Director
Terrie Curran, President Global Inflammation & Immunology Franchise
Michael Pehl, President Hematology & Oncology
Mark Alles, President, COO and Director
Alise Reicin, President - Global Clinical Development
Jonathan Biller, Executive Vice President General Counsel
Julia Haller, Director
Robert Hershberg, Chief Scientific Officer
Jacqualyn Fouse, President of Global Hematology and Oncology and Director
Ernest Mario, Independent Director
Scott Smith, President - Inflammation & Immunology
Thomas Daniel, Executive Vice President and Presidentident - Research and Early Development
Richard Barker, Independent Director
Michael Casey, Lead Independent Director

Celgene Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Celgene a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

Pair Trading with Celgene

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Celgene position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Celgene will appreciate offsetting losses from the drop in the long position's value.
The ability to find closely correlated positions to Newell Brands could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Newell Brands when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Newell Brands - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Newell Brands to buy it.
The correlation of Newell Brands is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Newell Brands moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Newell Brands moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Newell Brands can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching
Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in bureau of economic analysis.
You can also try the Idea Optimizer module to use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio .

Other Consideration for investing in Celgene Stock

If you are still planning to invest in Celgene check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Celgene's history and understand the potential risks before investing.
Odds Of Bankruptcy
Get analysis of equity chance of financial distress in the next 2 years
Efficient Frontier
Plot and analyze your portfolio and positions against risk-return landscape of the market.
Volatility Analysis
Get historical volatility and risk analysis based on latest market data
Equity Valuation
Check real value of public entities based on technical and fundamental data
Portfolio Analyzer
Portfolio analysis module that provides access to portfolio diagnostics and optimization engine
Share Portfolio
Track or share privately all of your investments from the convenience of any device
ETFs
Find actively traded Exchange Traded Funds (ETF) from around the world
Portfolio Comparator
Compare the composition, asset allocations and performance of any two portfolios in your account
Alpha Finder
Use alpha and beta coefficients to find investment opportunities after accounting for the risk